REGN
Regeneron Pharmaceuticals, Inc.
Price performance
Oct 2, 2026About
Company activity
24 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 5d | REGN | 8-K | Regeneron Pharmaceuticals Grants New Equity Awards to CEO and CSO | — | — | — |
| 07/30 | REGN | 8-K | Regeneron Reports Strong Q2 2026 Financial Results with Revenue Growth and Product Sales Increases | — | — | — |
| 07/06 | REGN | 8-K | Regeneron Pharmaceuticals Expects Q2 2026 Earnings Hit from IPR&D Charge | — | — | — |
| 06/17 | REGN | 8-K | Regeneron Pharmaceuticals Announces Results of 2026 Annual Meeting of Shareholders | — | — | — |
| 04/29 | REGN | 8-K | Regeneron Reports Strong Q1 2026 Financial Results and Authorizes New Share Repurchase Program | — | — | — |
| 04/08 | REGN | 8-K | Regeneron Pharmaceuticals Announces Expected Q1 2026 IPR&D Charge | — | — | — |
| 01/30 | REGN | 8-K | Regeneron Reports Q4 and Full Year 2025 Financial Results | — | — | — |
| 01/12 | REGN | 8-K | Regeneron Provides Q4 2025 Corporate Update: Financial Outlook and Charges | — | — | — |
| 10/28/25 | REGN | 8-K | Regeneron Announces Third Quarter 2025 Financial Results and Business Update | — | — | — |
| 10/06/25 | REGN | 8-K | Regeneron Pharmaceuticals Announces Acquired IPR&D Charge | — | — | — |
| 08/01/25 | REGN | 8-K | Regeneron Pharmaceuticals Reports Strong Second Quarter 2025 Results and Business Updates | — | — | — |
| 06/18/25 | REGN | 8-K | Regeneron Pharmaceuticals Shareholder Voting Results Announced | — | — | — |
| 04/29/25 | REGN | 8-K | Regeneron Reports First Quarter 2025 Financial Results and Pipeline Updates | — | — | — |
| 02/04/25 | REGN | 8-K | Regeneron Initiates Quarterly Dividend and Expands Share Repurchase Program | — | — | — |
| 01/13/25 | REGN | 8-K | Regeneron Provides Business Updates at J.P. Morgan Healthcare Conference | — | — | — |
| 10/31/24 | REGN | 8-K | Regeneron Reports Strong Q3 2024 Results with 11% Revenue Growth and Dupixent COPD Approval | — | — | — |
| 10/07/24 | REGN | 8-K | Regeneron Pharmaceuticals Expects $56M IPR&D Charge for Q3 2024 | — | — | — |
| 08/01/24 | REGN | 8-K | Regeneron Reports Strong Q2 2024 Financial Results with Revenue Growth and Expanded Pipeline | — | — | — |
| 07/08/24 | REGN | 8-K | Regeneron Pharmaceuticals Q2 2024 Financial Results Estimate | — | — | — |
| 06/20/24 | REGN | 8-K | Regeneron Pharmaceuticals Shareholder Votes on 2024 Annual Meeting Proposals | — | — | — |
| 05/02/24 | REGN | 8-K | Regeneron Pharmaceuticals Reports Q1 2024 Financial Results and Business Updates | — | — | — |
| 02/02/24 | REGN | 8-K | Regeneron Pharmaceuticals Reports Q4 2023 Financial Results | — | — | — |
| 01/31/24 | REGN | 8-K | Regeneron Pharmaceuticals Appoints New CFO and Controller | — | — | — |
| 01/08/24 | REGN | 8-K | Regeneron Pharmaceuticals Corporate Update on Q4 2023 Financial Results | — | — | — |
REGN filing record
Regeneron Pharmaceuticals, Inc. (REGN): 24 8-K filings summarized, the most recent on Sep 30, 2026.
What the 8-K filings said
- Sep 30, 2026 · high impact
Regeneron Pharmaceuticals, Inc. has granted new equity awards to its CEO and CSO, Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., respectively. These performance share units (PSUs) are designed to drive long-term value creation and are contingent on achieving specific pipeline and commercial…
Regeneron Pharmaceuticals Grants New Equity Awards to CEO and CSO - Jul 30, 2026 · medium impact
Regeneron Pharmaceuticals, Inc. announced its financial and operating results for the second quarter of 2026, reporting a 17% increase in total revenues to $4.3 billion. Net product sales for Dupixent increased by 38% to a new all-time high of $6.0 billion, EYLEA HD net sales increased by 52% to $596 million, and…
Regeneron Reports Strong Q2 2026 Financial Results with Revenue Growth and Product Sales Increases - Jul 6, 2026 · high impact
Regeneron Pharmaceuticals, Inc. expects a $127 million acquired in-process research and development (IPR&D) charge for Q2 2026, negatively impacting GAAP and non-GAAP net income per diluted share by approximately $1.00. This charge relates to up-front and opt-in payments in connection with collaboration and licensing…
Regeneron Pharmaceuticals Expects Q2 2026 Earnings Hit from IPR&D Charge - Jun 17, 2026 · medium impact
Regeneron Pharmaceuticals, Inc. reported the outcomes of its 2026 Annual Meeting of Shareholders held on June 12, 2026. Shareholders elected five new Class II directors and ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending…
Regeneron Pharmaceuticals Announces Results of 2026 Annual Meeting of Shareholders - Apr 29, 2026 · medium impact
Regeneron Pharmaceuticals, Inc. reported strong financial results for the first quarter of 2026, with total revenues increasing by 19% to $3.6 billion. The company saw significant growth in net product sales, particularly for Dupixent and EYLEA HD. Regeneron also authorized a new $3.0 billion share repurchase program.…
Regeneron Reports Strong Q1 2026 Financial Results and Authorizes New Share Repurchase Program
SEC filings in the last five years
- 40 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 8-K/A